First to market strategy establishes a cosmeceutical
brand in the fast-growing Latin
America skin care sector with innovative CBD-based consumer
products
TORONTO, Sept. 28, 2018 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQB:
KHRNF) (Frankfurt: A2JMZC), an
integrated medical cannabis company with its core operations in
Colombia, announced today the
creation of Khiron Wellness, and the launch of Kuida®, its first
CBD-based skincare brand. With this achievement, Kuida® becomes the
first mass-market CBD-based brand approved by INVIMA, Colombia´s
health agency, and available for sale in Colombia.
Khiron's Wellness business unit is focused on cosmeceutical and
nutraceutical products, offering the full benefits of cannabis to
consumers across Latin
America.
Kuida® is the first brand in Colombia that brings the benefits of
Cannabidiol (CBD) to a comprehensive portfolio of skin and body
care products for women. Kuida® advances CBD and innovative
cosmeceutical ingredients to create our proprietary CBDERM®
technology, which is proven to be three times more antioxidant than
vitamin E, with anti-aging properties, quick absorption and light
textures to improve the skin penetration of CBD.
The full Kuida® product portfolio can be found at
www.Kuidaskincare.com
Alvaro Torres, Co-founder and
Chief Executive Officer stated, "In keeping with our stated
strategy, the Khiron Wellness business unit and launch of Kuida®
leverages our global medical cannabis expertise to enter a
fast-growing category with immediate revenue generation based on a
disruptive, innovative and first-to-market product strategy. We
will be launching Kuida® across the region, while developing
innovative consumer packaged goods into our pipeline. Additionally,
Khiron will continue to achieve its milestones related to the
ongoing expansion of our cannabis cultivation, development of
medical products, and clinics rollout."
According to Euromonitor, the skincare market in Colombia is over US $5.6 Billion in annual sales, with a growth rate
of 6% in the past five years. Further, the Latin American skincare
market is anticipated to reach US $110
Billion annually by 2020.
Andres Galofre, Co-founder and
Chief Commercial Officer stated, "I would like to congratulate our
team for their dedication in bringing Kuida®, the first
INVIMA-approved, CBD-based skincare brand to the market. We
understand and promote the benefits of CBD-based cosmeceuticals and
the potential for Kuida® to have a positive impact on women's
lives, beauty, and well-being across Latin America".
Kuida® will launch and will be a major sponsor at the XVII Feria
de Belleza y Salud taking place in Bogota, Colombia from October 3-7, 2018. This event is the largest
health and beauty conference in Colombia attracting more than 55,000 attendees
to discover new products and latest trends in the industry. Full
event details can be found at www.feriabellezaysalud.com
Kuida® Announces Ms. Catalina
Aristizabal as Brand Ambassador
Khiron launches Kuida® with one of Colombia´s top influencers
and recognized personality, Ms. Catalina
Aristizabal, as ambassador for the Kuida® brand. A model,
actress and health advocate, Ms. Aristizabal has starred in hit TV
programs, in film, as a judge on the popular Colombia's Next Top Model TV show, and hostess
of Colombia´s top rated reality show over the last two years.
"Whether on screen or at home with my family, I work hard to live a
healthy life every single day. Kuida® is already a part of my daily
skincare routine and I am proud to support the brand in helping
other women feel beautiful", comments Mrs. Aristizabal.
With a prominent social media presence, including almost 1.5
million Instagram followers, and a well-known passion for healthy
living, Mrs. Aristizabal will represent Kuida® at beauty and
lifestyle events, and feature prominently in Kuida®´s marketing
plan, complementing the more than 300 Kuida® brand influencers.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXv: KRHN, OTCQB: KHRNF,
Frankfurt: A2JMZC) ("Khiron" or
the "Company") is positioned to be the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both tetrahydrocannabinol (THC) and
cannabidiol (CBD) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.